In silico analysis to identify vaccine candidates common to multiple serotypes of Shigella and evaluation of their immunogenicity
Name:
S1Fig.xlsx
Size:
333.5Kb
Format:
Microsoft Excel 2007
Description:
Supplemental files
Name:
S2Fig.tif
Size:
158.8Kb
Format:
TIFF image
Description:
Supplemental files
Name:
S3Fig.xlsx
Size:
2.525Mb
Format:
Microsoft Excel 2007
Description:
Supplemental files
Type
ArticleKAUST Department
Biological and Environmental Sciences and Engineering (BESE) DivisionComputational Bioscience Research Center (CBRC)
Pathogen Genomics Laboratory
Date
2017-08-02Permanent link to this record
http://hdl.handle.net/10754/625314
Metadata
Show full item recordAbstract
Shigellosis or bacillary dysentery is an important cause of diarrhea, with the majority of the cases occurring in developing countries. Considering the high disease burden, increasing antibiotic resistance, serotype-specific immunity and the post-infectious sequelae associated with shigellosis, there is a pressing need of an effective vaccine against multiple serotypes of the pathogen. In the present study, we used bio-informatics approach to identify antigens shared among multiple serotypes of Shigella spp. This approach led to the identification of many immunogenic peptides. The five most promising peptides based on MHC binding efficiency were a putative lipoprotein (EL PGI I), a putative heat shock protein (EL PGI II), Spa32 (EL PGI III), IcsB (EL PGI IV) and a hypothetical protein (EL PGI V). These peptides were synthesized and the immunogenicity was evaluated in BALB/c mice by ELISA and cytokine assays. The putative heat shock protein (HSP) and the hypothetical protein elicited good humoral response, whereas putative lipoprotein, Spa32 and IcsB elicited good T-cell response as revealed by increased IFN-γ and TNF-α cytokine levels. The patient sera from confirmed cases of shigellosis were also evaluated for the presence of peptide specific antibodies with significant IgG and IgA antibodies against the HSP and the hypothetical protein, bestowing them as potential future vaccine candidates. The antigens reported in this study are novel and have not been tested as vaccine candidates against Shigella. This study offers time and cost-effective way of identifying unprecedented immunogenic antigens to be used as potential vaccine candidates. Moreover, this approach should easily be extendable to find new potential vaccine candidates for other pathogenic bacteria.Citation
Pahil S, Taneja N, Ansari HR, Raghava GPS (2017) In silico analysis to identify vaccine candidates common to multiple serotypes of Shigella and evaluation of their immunogenicity. PLOS ONE 12: e0180505. Available: http://dx.doi.org/10.1371/journal.pone.0180505.Sponsors
We wish to thank the Indian Council of Medical Research (ICMR), New Delhi, India. The work has been granted an international patent by WIPO (World Intellectual Property Organization) in collaboration with ICMR. The Indian Council of Medical Research (ICMR), New Delhi, provided research fellowship to SP for carrying out this work as a part of her PhD thesis. The Department of Medical Microbiology, PGIMER, Chandigarh, India also funded a part of this work.Publisher
Public Library of Science (PLoS)Journal
PLOS ONEae974a485f413a2113503eed53cd6c53
10.1371/journal.pone.0180505
Scopus Count
Except where otherwise noted, this item's license is described as This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.